| OMB APPROVAL | ||
| OMB Number: | 3235-0060 | |
| Expires: | April 30, 2015 | |
| Estimated average burden | ||
| hours per response | 5.71 | |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 21, 2014
| CANCER GENETICS, INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 001-35817 | 04-3462475 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 201 Route 17 North 2nd Floor, Rutherford, New Jersey | 07070 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:(201) 528-9200
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On October 21, 2014, Cancer Genetics, Inc. issued a press release to report the issuance of U.S. Patent No. 8,865,882 (U.S. Application No. 13/227,027) entitled “Methods for Detecting Human Papilloma Virus-Associated Cancers” for FHACT®, a DNA FISH-probe test that detects the presence of four chromosomal abnormalities indicative of HPV-associated cancers. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is filed with this report:
Exhibit No. Description
99.1 Press release announcing issuance of U.S. Patent for FHACT®.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CANCER GENETICS, INC. | |||
| (Registrant) | |||
| /s/ Edward J. Sitar | |||
| Name: EdwardJ. Sitar | |||
| Title: Chief Financial Officer | |||
Dated: October 22, 2014